Related Experiment Video
Updated: Jan 2, 2026
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
2.2K
Telemedicine Technologies and Tuberculosis Management: A Randomized Controlled Trial
Summary
Video directly observed therapy (VDOT) offers comparable tuberculosis treatment success to traditional directly observed therapy (DOT) while significantly reducing time and cost. This telehealth approach is highly acceptable to patients and providers, proving a valuable alternative for TB management.
Area of Science:
- Public Health
- Infectious Diseases
- Telemedicine
Background:
- Directly Observed Therapy (DOT) has been the standard for tuberculosis (TB) treatment since the 1990s.
- DOT presents logistical challenges for patients and healthcare providers.
- Telehealth offers a potential alternative delivery method for TB treatment observation.
Purpose of the Study:
- To assess the clinical and cost benefits of Video Directly Observed Therapy (VDOT) compared to traditional DOT.
- To evaluate treatment adherence, patient satisfaction, and resource utilization for both VDOT and DOT.
Main Methods:
- A prospective randomized controlled trial involving adults with bacteriologically confirmed pulmonary TB.
- Participants were randomized to either VDOT or DOT groups.
- Outcomes included TB treatment results (WHO criteria), adherence, satisfaction, time, and cost.
Main Results:
- Treatment completion rates were high and statistically similar between VDOT (96.1%) and DOT (94.6%).
- VDOT significantly reduced observation time per dose (16.5 min vs. 44.1 min for DOT) and cost (￥34.3 vs. ￥71.6 for DOT).
- Patients reported higher convenience, comfort, and willingness to recommend VDOT over DOT.
Conclusions:
- VDOT provides effective direct observation for TB patients via mobile devices, demonstrating high acceptability among patients and providers.
- VDOT is a time-efficient and cost-effective method for TB treatment observation.
- The cost savings from VDOT can be reallocated to other essential areas of TB control.
Related Concept Videos
01:28Pulmonary Tuberculosis V
500
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
500
01:26Pulmonary Tuberculosis IV
449
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
449
01:28Pulmonary Tuberculosis II
1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
01:29Pulmonary Tuberculosis I
779
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
779
01:31Pulmonary Tuberculosis III
849
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
849
01:29Therapeutic Drug Monitoring: Affecting Factors
151
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
151